银屑病是一种以表皮角质形成细胞过度增殖和异常分化为主要特征的慢性炎症性皮肤病。一种有趣的酚类化合物,即quebecol(2,3,3-三-(3-甲氧基-4-羟基苯基)-1-丙醇)(化合物1,CPD1),2011年从枫糖浆中分离出来,最近合成。quebecol及其衍生物2,3,3-三(3-羟基-4-甲氧基苯基)丙烯酸乙酯(化合物2,CPD2)和双(4-羟基-3-甲氧基苯基)甲烷(化合物3,CPD3)已显示出抗增殖和抗炎潜力,使他们成为治疗牛皮癣的有希望的候选人。本研究旨在评估quebecol及其衍生物对根据自组装方法生产的牛皮癣皮肤替代品的抗牛皮癣潜力。对CPD1,CPD2和CPD3进行磺罗丹明B(SRB)测定,确定抑制20%细胞生长的浓度(IC20),其IC20值为400、150和350μM,分别。在这些浓度下,细胞活力为97%,94%和97%,分别。对比对照甲氨蝶呤(MTX)在734μM的浓度下具有85%的细胞活力。用CPD1,CPD2和CPD3治疗的牛皮癣皮肤替代品的组织学分析显示,与未治疗的牛皮癣替代品相比,表皮厚度显着降低。如Ki67免疫荧光染色所示,这与角质形成细胞增殖的减少一致。分化标记物(角蛋白14,总蛋白和loricrin)的免疫荧光染色显示表皮分化改善。一起来看,这些结果凸显了quebecol及其衍生物治疗牛皮癣的潜力。
Psoriasis is a chronic inflammatory skin disease mainly characterized by the hyperproliferation and abnormal differentiation of the epidermal keratinocytes. An interesting phenolic compound, namely quebecol (2,3,3-tri-(3-methoxy-4-hydroxyphenyl)-1-propanol) (compound 1, CPD1), was isolated from maple syrup in 2011 and was recently synthesized. Quebecol and its derivatives ethyl 2,3,3-tris(3-hydroxy-4-methoxyphenyl)propenoate (compound 2, CPD2) and bis(4-hydroxy-3-methoxyphenyl)methane (compound 3, CPD3) have shown antiproliferative and anti-inflammatory potential, making them promising candidates for the treatment of psoriasis. This study aimed to evaluate the antipsoriatic potential of quebecol and its derivatives on psoriatic skin substitutes produced according to the self-assembly method. A sulforhodamine B (SRB) assay determining the concentration that inhibits 20% of cell growth (IC20) was performed for CPD1, CPD2 and CPD3, and their IC20 values were 400, 150 and 350 μM, respectively. At these concentrations, cell viability was 97%, 94% and 97%, respectively. The comparative control methotrexate (MTX) had a cell viability of 85% at a concentration of 734 μM. Histological analyses of psoriatic skin substitutes treated with CPD1, CPD2 and CPD3 exhibited significantly reduced epidermal thickness compared with untreated psoriatic substitutes, which agreed with a decrease in keratinocyte proliferation as shown by Ki67 immunofluorescence staining. The immunofluorescence staining of differentiation markers (keratin 14, involucrin and loricrin) showed improved epidermal differentiation. Taken together, these results highlight the promising potential of quebecol and its derivatives for the treatment of psoriasis.